Tianjin Medical Journal ›› 2023, Vol. 51 ›› Issue (8): 834-840.doi: 10.11958/20221627
• Experimental Research • Previous Articles Next Articles
QIN Zongbi(), XU Aiqin, CAI Xiang, QIU Baiyi, WANG Shoufan, LI Linghua, ZHU Lihong
Received:
2022-10-09
Revised:
2023-01-12
Published:
2023-08-15
Online:
2023-08-10
QIN Zongbi, XU Aiqin, CAI Xiang, QIU Baiyi, WANG Shoufan, LI Linghua, ZHU Lihong. Effects of berberine on skin damage in rats with chronic eczema by regulating PI3K/AKT/NF-κB signaling pathway[J]. Tianjin Medical Journal, 2023, 51(8): 834-840.
CLC Number:
组别 | 给药0周 | 给药1周 | 给药2周 |
---|---|---|---|
慢性湿疹组 | 7.95±0.90 | 8.15±0.86 | 7.65±0.84 |
黄连素低剂量组 | 8.05±0.84 | 6.35±0.68a | 5.20±0.75a |
黄连素中剂量组 | 7.80±0.96 | 5.60±0.74a | 4.05±0.68ab |
黄连素高剂量组 | 8.00±0.85 | 4.05±0.62abc | 1.85±0.59abc |
泼尼松组 | 7.90±0.92 | 4.50±0.75abc | 2.60±0.72abc |
F | 0.115 | 49.105** | 100.996** |
Tab.1 Comparison of EASI scores of rats between the five groups
组别 | 给药0周 | 给药1周 | 给药2周 |
---|---|---|---|
慢性湿疹组 | 7.95±0.90 | 8.15±0.86 | 7.65±0.84 |
黄连素低剂量组 | 8.05±0.84 | 6.35±0.68a | 5.20±0.75a |
黄连素中剂量组 | 7.80±0.96 | 5.60±0.74a | 4.05±0.68ab |
黄连素高剂量组 | 8.00±0.85 | 4.05±0.62abc | 1.85±0.59abc |
泼尼松组 | 7.90±0.92 | 4.50±0.75abc | 2.60±0.72abc |
F | 0.115 | 49.105** | 100.996** |
组别 | 组胺/(μg/L) | GRP/(ng/L) | IgE/(μg/L) |
---|---|---|---|
对照组 | 18.96±3.21 | 8.29±1.45 | 12.51±2.54 |
慢性湿疹组 | 85.27±6.52a | 25.64±3.36a | 32.84±4.50a |
黄连素低剂量组 | 73.16±5.48b | 19.52±3.01b | 28.16±3.38 |
黄连素中剂量组 | 58.26±5.34bc | 14.35±2.87b | 22.35±4.06bc |
黄连素高剂量组 | 34.58±4.65bcd | 10.16±2.05bcd | 17.17±3.65bcd |
泼尼松组 | 39.01±5.18bcd | 11.08±1.94bc | 18.02±3.27bc |
F | 237.003** | 67.590** | 43.445** |
Tab.2 Comparison of serum histamine, GRP and IgE levels of rats between the six groups
组别 | 组胺/(μg/L) | GRP/(ng/L) | IgE/(μg/L) |
---|---|---|---|
对照组 | 18.96±3.21 | 8.29±1.45 | 12.51±2.54 |
慢性湿疹组 | 85.27±6.52a | 25.64±3.36a | 32.84±4.50a |
黄连素低剂量组 | 73.16±5.48b | 19.52±3.01b | 28.16±3.38 |
黄连素中剂量组 | 58.26±5.34bc | 14.35±2.87b | 22.35±4.06bc |
黄连素高剂量组 | 34.58±4.65bcd | 10.16±2.05bcd | 17.17±3.65bcd |
泼尼松组 | 39.01±5.18bcd | 11.08±1.94bc | 18.02±3.27bc |
F | 237.003** | 67.590** | 43.445** |
组别 | IL-4 | IL-6 |
---|---|---|
对照组 | 34.28±5.01 | 46.58±5.86 |
慢性湿疹组 | 75.32±6.85a | 136.19±8.42a |
黄连素低剂量组 | 66.15±6.42b | 112.34±8.06b |
黄连素中剂量组 | 55.26±5.86bc | 98.62±7.68bc |
黄连素高剂量组 | 42.89±5.62bcd | 65.24±6.32bcd |
泼尼松组 | 40.51±5.13bcd | 68.41±6.84bcd |
F | 74.910** | 214.422** |
组别 | TNF-α | IFN-γ |
对照组 | 56.48±6.35 | 39.52±3.15 |
慢性湿疹组 | 121.52±8.51a | 21.34±2.37a |
黄连素低剂量组 | 105.37±8.62b | 26.21±2.85b |
黄连素中剂量组 | 86.42±7.96bc | 31.16±2.64bc |
黄连素高剂量组 | 70.36±6.85bcd | 35.08±2.35bcd |
泼尼松组 | 71.58±7.03bcd | 34.65±2.58bc |
F | 102.366** | 61.164** |
Tab.3 Comparison of serum IL-4, IL-6, TNF-α and IFN-γ levels of rats between the six groups
组别 | IL-4 | IL-6 |
---|---|---|
对照组 | 34.28±5.01 | 46.58±5.86 |
慢性湿疹组 | 75.32±6.85a | 136.19±8.42a |
黄连素低剂量组 | 66.15±6.42b | 112.34±8.06b |
黄连素中剂量组 | 55.26±5.86bc | 98.62±7.68bc |
黄连素高剂量组 | 42.89±5.62bcd | 65.24±6.32bcd |
泼尼松组 | 40.51±5.13bcd | 68.41±6.84bcd |
F | 74.910** | 214.422** |
组别 | TNF-α | IFN-γ |
对照组 | 56.48±6.35 | 39.52±3.15 |
慢性湿疹组 | 121.52±8.51a | 21.34±2.37a |
黄连素低剂量组 | 105.37±8.62b | 26.21±2.85b |
黄连素中剂量组 | 86.42±7.96bc | 31.16±2.64bc |
黄连素高剂量组 | 70.36±6.85bcd | 35.08±2.35bcd |
泼尼松组 | 71.58±7.03bcd | 34.65±2.58bc |
F | 102.366** | 61.164** |
组别 | IL-4 | IL-6 |
---|---|---|
对照组 | 0.28±0.05 | 0.31±0.06 |
慢性湿疹组 | 0.72±0.07a | 0.68±0.07a |
黄连素低剂量组 | 0.64±0.06 | 0.59±0.06b |
黄连素中剂量组 | 0.51±0.07bc | 0.51±0.05bc |
黄连素高剂量组 | 0.38±0.06bcd | 0.40±0.06bcd |
泼尼松组 | 0.36±0.05bcd | 0.41±0.06bcd |
F | 80.991** | 51.266** |
组别 | TNF-α | IFN-γ |
对照组 | 0.38±0.06 | 0.45±0.04 |
慢性湿疹组 | 0.75±0.08a | 0.19±0.03a |
黄连素低剂量组 | 0.65±0.07b | 0.26±0.03b |
黄连素中剂量组 | 0.54±0.08bc | 0.35±0.04bc |
黄连素高剂量组 | 0.43±0.06bcd | 0.41±0.04bcd |
泼尼松组 | 0.45±0.07bc | 0.42±0.03bcd |
F | 40.966** | 83.413** |
Tab.4 Comparison of IL-4, IL-6, TNF-α and IFN-γ protein expression levels in skin lesions of rats between the six groups
组别 | IL-4 | IL-6 |
---|---|---|
对照组 | 0.28±0.05 | 0.31±0.06 |
慢性湿疹组 | 0.72±0.07a | 0.68±0.07a |
黄连素低剂量组 | 0.64±0.06 | 0.59±0.06b |
黄连素中剂量组 | 0.51±0.07bc | 0.51±0.05bc |
黄连素高剂量组 | 0.38±0.06bcd | 0.40±0.06bcd |
泼尼松组 | 0.36±0.05bcd | 0.41±0.06bcd |
F | 80.991** | 51.266** |
组别 | TNF-α | IFN-γ |
对照组 | 0.38±0.06 | 0.45±0.04 |
慢性湿疹组 | 0.75±0.08a | 0.19±0.03a |
黄连素低剂量组 | 0.65±0.07b | 0.26±0.03b |
黄连素中剂量组 | 0.54±0.08bc | 0.35±0.04bc |
黄连素高剂量组 | 0.43±0.06bcd | 0.41±0.04bcd |
泼尼松组 | 0.45±0.07bc | 0.42±0.03bcd |
F | 40.966** | 83.413** |
组别 | p-PI3K/PI3K | p-AKT/AKT | ||
---|---|---|---|---|
对照组 | 0.51±0.05 | 0.45±0.04 | ||
慢性湿疹组 | 0.96±0.06a | 0.93±0.05a | ||
黄连素低剂量组 | 0.89±0.05b | 0.86±0.06b | ||
黄连素中剂量组 | 0.82±0.04bc | 0.74±0.05bc | ||
黄连素高剂量组 | 0.70±0.05bcd | 0.63±0.04bcd | ||
泼尼松组 | 0.75±0.05bcd | 0.65±0.05bcd | ||
F | 99.382** | 125.371** | ||
组别 | p-NF-κB p65/NF-κB p65 | p-IκBα/IκBα | ||
对照组 | 0.41±0.04 | 0.36±0.03 | ||
慢性湿疹组 | 0.85±0.06a | 0.79±0.05a | ||
黄连素低剂量组 | 0.76±0.06b | 0.70±0.04b | ||
黄连素中剂量组 | 0.66±0.05bc | 0.61±0.04bc | ||
黄连素高剂量组 | 0.54±0.04bcd | 0.52±0.05bcd | ||
泼尼松组 | 0.57±0.05bcd | 0.53±0.03bcd | ||
F | 98.403** | 136.500** |
Tab.5 Comparison of p-PI3K/PI3K, p-AKT/AKT, p-NF-κB p65/NF-κB p65 and p-IκBα/IκBα ratio in skin lesions of rats between the six groups
组别 | p-PI3K/PI3K | p-AKT/AKT | ||
---|---|---|---|---|
对照组 | 0.51±0.05 | 0.45±0.04 | ||
慢性湿疹组 | 0.96±0.06a | 0.93±0.05a | ||
黄连素低剂量组 | 0.89±0.05b | 0.86±0.06b | ||
黄连素中剂量组 | 0.82±0.04bc | 0.74±0.05bc | ||
黄连素高剂量组 | 0.70±0.05bcd | 0.63±0.04bcd | ||
泼尼松组 | 0.75±0.05bcd | 0.65±0.05bcd | ||
F | 99.382** | 125.371** | ||
组别 | p-NF-κB p65/NF-κB p65 | p-IκBα/IκBα | ||
对照组 | 0.41±0.04 | 0.36±0.03 | ||
慢性湿疹组 | 0.85±0.06a | 0.79±0.05a | ||
黄连素低剂量组 | 0.76±0.06b | 0.70±0.04b | ||
黄连素中剂量组 | 0.66±0.05bc | 0.61±0.04bc | ||
黄连素高剂量组 | 0.54±0.04bcd | 0.52±0.05bcd | ||
泼尼松组 | 0.57±0.05bcd | 0.53±0.03bcd | ||
F | 98.403** | 136.500** |
[1] | BARRETT A, HAHN-PEDERSEN J, KRAGH N, et al. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults[J]. Patient, 2019, 12(5):445-459. doi:10.1007/s40271-019-00373-y. |
[2] | DUBIN C, DEL DUCA E, GUTTMAN-YASSKY E. Drugs for the treatment of chronic hand eczema: successes and key challenges[J]. Ther Clin Risk Manag, 2020, 16:1319-1332. doi:10.2147/TCRM.S292504. |
[3] | 陈兴, 黄丽霞, 李忻红, 等. 中药外治湿疹用药规律的数据挖掘研究[J]. 辽宁中医杂志, 2021, 9(1):86-90. |
CHEN X, HUANG L X, LI Q H, et al. Data mining research on medication laws of external treatment of eczema with traditional Chinese medicine[J]. Liaoning J Tradit Chin Med, 2021, 9(1):86-90. doi:10.13192/j.issn.1000-1719.2021.09.023. | |
[4] | 赖亭吉. 消银颗粒联合卤米松乳膏治疗慢性湿疹疗效观察[J]. 东南大学学报:医学版, 2020, 39(2):190-192. |
LAI T J. Curative effect of Xiaoyin granules combined with halometasone cream on chronic eczema[J]. J Southeast Univ(Med Sci Edi), 2020, 39(2):190-192. doi:CNKI:SUN:NJTD.0.2020-02-011. | |
[5] | WANG J, WANG L, LOU G H, et al. Coptidis Rhizoma:a comprehensive review of its traditional uses,botany,phytochemistry,pharmacology and toxicology[J]. Pharm Biol, 2019, 57(1):193-225. doi:10.1080/13880209.2019.1577466. |
[6] | ANDOH T, YOSHIHISA Y, REHMAN M U, et al. Berberine induces anti-atopic dermatitis effects through the downregulation of cutaneous EIF3F and MALT1 in NC/Nga mice with atopy-like dermatitis[J]. Biochem Pharmacol, 2021, 185:114439. doi:10.1016/j.bcp.2021.114439. |
[7] | 郭斐斐, 杜雪洋, 李丹, 等. 小檗碱乳膏对大鼠耳廓复合痤疮模型皮损及IGF-1,DHEA的影响[J]. 中国皮肤性病学杂志, 2021, 35(10):1103-1110. |
GUO F F, DU X Y, LI D, et al. Effects of berberine cream on skin lesions,IGF-1 and DHEA in rats with auricle acne[J]. Chin J Dermatovenereol, 2021, 35(10):1103-1110. doi:10.13735/j.cjdv.1001-7089.202012139. | |
[8] | 张荣榕, 李宁, 邵帅, 等. 基于P38MAPK信号通路探讨加味黄连膏对小鼠湿疹模型的影响[J]. 中国医院药学杂志, 2020, 40(16):1728-1732. |
ZHANG R R, LI N, SHAO S, et al. Effect of modified huanglian ointment on mouse eczema model based on p38MAPK signal pathway[J]. Chin J Hosp Pharm, 2020, 40(16):1728-1732. doi:10.13286/j.1001-5213.2020.16.08. | |
[9] | 邹效. 黄连素在皮肤疾病中的应用[J]. 科学养生, 2021, 2(3):294. |
ZOU X. Application of berberine in skin diseases[J]. Regimen, 2021, 2(3):294. | |
[10] | 胡志平, 何绍前, 王传明, 等. 甘草酸抑制PI3K/AKT/NF-κB减轻胶原诱导型类风湿关节炎大鼠炎症反应[J]. 中国老年学杂志, 2020, 40(13):2852-2856. |
HU Z P, HE S Q, WANG C M, et al. Glycyrrhizic acid inhibits PI3K/AKT/NF-κB alleviates the inflammatory response in rats with collagen induced rheumatoid arthritis[J]. Chin J Gerontol, 2020, 40(13):2852-2856. doi:10.3969/j.issn.1005-9202.2020.13.054. | |
[11] | 谢婷妃, 袁树珍, 隋晓露, 等. 尿酸诱导人肾小管上皮细胞炎症损伤中PI3K/AKT/NF-κB信号通路的调控机制[J]. 中华肾脏病杂志, 2021, 37(1):36-42. |
XIE T F, YUAN S Z, SUI X L, et al. Uric acid induces inflammatory injury in HK-2 cells via PI3K/AKT/NF-κB signaling pathway[J]. Chin J Nephrol, 2021, 37(1):36-42. doi:10.3760/cma.j.cn441217-20200618-00006. | |
[12] | 朱雨晴, 俞彩霞, 朱杰, 等. 柏蛇湿疹膏对急性,慢性湿疹大鼠皮肤及炎症因子的影响[J]. 中国地方病防治杂志, 2021, 36(1):16-18. |
ZHU Y Q, YU C X, ZHU J, et al. Effect of cypress eczema cream on skin and inflammatory factors in rats with acute and chronic eczema[J]. Chin J Ctrl Endem Dis, 2021, 36(1):16-18. | |
[13] | 郑琳琳, 王星星, 朱新景, 等. 止痛消炎膏对慢性湿疹模型小鼠皮损及TEWL、SCH、湿度的影响[J]. 辽宁中医杂志, 2022, 49(5):192-195. |
ZHENG L L, WANG X X, ZHU X J, et al. Effect of Zhitong Xiaoyan Ointment on skin lesions,TEWL,SCH and humidity of chronic atopic dermatitis model mice[J]. Liaoning J Tradit Chin Med, 2022, 49(5):192-195. | |
[14] | 汪园园, 金明华, 黄颖娟, 等. 苓桂术甘汤联合热量限摄对湿疹模型大鼠皮损的影响及其机制分析[J]. 中国中西医结合杂志, 2020, 40(4):465-469. |
WANG Y Y, JIN M H, HAUNG Y J, et al. Effect of Calorie-restriction Therapy combined Linggui Zhugan Decoction on eczema model rats[J]. Chin J Integ Trad Western Med, 2020, 40(4):465-469. doi:10.7661/j.cjim.20190928.286. | |
[15] | 赵辨. 湿疹面积及严重度指数评分法[J]. 中华皮肤科杂志, 2004, 37(1):3-4. |
ZHAO B. Eczema area and severity index scoring method[J]. Chin J Dermatol, 2004, 37(1):3-4. doi:10.3760/j.issn:0412-4030.2004.01.002. | |
[16] | 刘影, 董燕, 孙道红, 等. 参苓白术散联合多磺酸黏多糖封包对老年慢性湿疹血虚风燥证患者炎症因子和外周血T淋巴细胞亚群的影响[J]. 中华中医药学刊, 2020, 38(5):166-169. |
LIU Y, DONG Y, SUN D H, et al. Effect of Shenling Baizhu Powder combined with Polysulfonic Acid Mucopolysaccharide Encapsulation on inflammatory cytokines and peripheral blood T lymphocyte subsets in elderly patients with chronic eczema and blood deficiency[J]. Chin Arch Trad Chin Med, 2020, 38(5):166-169. doi:10.13193/j.issn.1673-7717.2020.05.039. | |
[17] | JIANG Y, ZHAO L, CHEN Q, et al. Exploring the mechanism of berberine intervention in ulcerative colitis from the perspective of inflammation and immunity based on systemic pharmacology[J]. Evid Based Complement Alternat Med, 2021, 2021:9970240. doi:10.1155/2021/9970240. |
[18] | TEW X N, XIN LAU N J, CHELLAPPAN D K, et al. Immunological axis of berberine in managing inflammation underlying chronic respiratory inflammatory diseases[J]. Chem Biol Interact, 2020, 317:108947. doi:10.1016/j.cbi.2020.108947. |
[19] | WOLLENBERG A, BARBAROT S, BIEBER T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children:part Ⅱ[J]. J Eur Acad Dermatol Venereol, 2018, 32(6):850-878. doi:10.1111/jdv.14891. |
[20] | ZHOU X L, CHEN L L, WANG J F. Study on the antipruritic mechanism of Zanthoxylum bungeanum and Zanthoxylum schinifolium volatile oil on chronic eczema based on H1R and PAR-2 mediated GRPR pathway[J]. Allergol Immunopathol (Madr), 2022, 50(4):83-96. doi:10.15586/aei.v50i4.486. |
[21] | 唐学武, 王文革, 张俊红, 等. 脐血TSLP、IgE水平对早期婴儿湿疹的预测价值[J]. 中国皮肤性病学杂志, 2020, 34(8):879-883. |
TANG X W, WANG W G, ZHANG J H, et al. Predictive value of cord blood TSLP,IgE level for early infantile eczema[J]. Chin J Dermatovenereol, 2020, 34(8):879-883. doi:10.13735/j.cjdv.1001-7089.201911057. | |
[22] | 陶文婷, 陈姣姣, 高清华, 等. 小檗碱通过抑制Th1恢复IFN-γ/IL-4平衡减轻迟发型超敏反应[J]. 中国中医基础医学杂志, 2021, 27(3):423-426. |
TAO W T, CHEN J J, GAO Q H, et al. Berberine attenuates delayed type hypersensitivity by inhibiting Th1 and restoring IFN-γ/IL-4 balance[J]. J Basic Chin Med, 2021, 27(3):423-426. | |
[23] | LIU B, PIAO X, NIU W, et al. Kuijieyuan Decoction improved intestinal barrier injury of ulcerative colitis by affecting TLR4-dependent PI3K/AKT/NF-κB oxidative and inflammatory signaling and gut microbiota[J]. Front Pharmacol, 2020, 11:1036. doi:10.3389/fphar.2020.01036. |
[24] | ZHU Q, ENKHJARGAL B, HUANG L, et al. Aggf1 attenuates neuroinflammation and BBB disruption via PI3K/Akt/NF-κB pathway after subarachnoid hemorrhage in rats[J]. J Neuroinflammation, 2018, 15(1):178. doi:10.1186/s12974-018-1211-8. |
[25] | WANG L, MA H, XUE Y, et al. Berberine inhibits the ischemia-reperfusion injury induced inflammatory response and apoptosis of myocardial cells through the phosphoinositide 3-kinase/RAC-α serine/threonine-protein kinase and nuclear factor-κB signaling pathways[J]. Exp Ther Med, 2018, 15(2):1225-1232. doi:10.3892/etm.2017.5575. |
[26] | WU Y S, LI Z M, CHEN Y T, et al. Berberine improves inflammatory responses of diabetes mellitus in zucker diabetic fatty rats and insulin-resistant HepG2 cells through the PPM1B pathway[J]. J Immunol Res, 2020, 2020:2141508. doi:10.1155/2020/2141508. |
[1] | FAN Huihui, REN Yumei, TIAN Xinlei, ZHANG Kai, LI Xiaoli. Effects of Zhike Pingchuan Formula on airway inflammation and TLR4/TRAF6/NF-κB pathway in bronchial asthma mice [J]. Tianjin Medical Journal, 2024, 52(9): 924-929. |
[2] | JIA Weining, BAO Yaling, LEI Hui, YIN Xiaoning. The effect of prunella vulgaris extract on inflammatory response and peritoneal macrophages in septic mice [J]. Tianjin Medical Journal, 2024, 52(9): 930-935. |
[3] | WU Bo, ZHU Zhuonong, ZHENG Lijuan, CHEN Junru. Effects of matrine on inflammation, oxidative stress and wound healing in atopic dermatitis [J]. Tianjin Medical Journal, 2024, 52(6): 566-571. |
[4] | JIANG Tao, CHENG Hongyan, WU Qiong. Effect of Jaceosidin on inflammatory response in gestational diabetes mellitus rats by regulating SDF-1α/CXCR4 signaling pathway [J]. Tianjin Medical Journal, 2024, 52(6): 594-598. |
[5] | HUO Jingchen, WANG Yue, LI Hua, QIU Rong, SU Jingwei, WANG Zhuofan, YANG Jie. Predictive value of systemic immune inflammation index (SII) on long-term survival of patients with stage III squamous lung cancer treated with radical radiotherapy [J]. Tianjin Medical Journal, 2024, 52(6): 634-638. |
[6] | MU Jingran, LUO Yan, LIANG Xuan, XU Tao, ZENG Junwei, LIU Xiaohong. Research progress on the activation of complement system is involved in the pathogenesis of Alzheimer's disease [J]. Tianjin Medical Journal, 2024, 52(6): 663-668. |
[7] | HAN Zhengyi, LI Rui, CHEN Qi, WANG Jiayou, SHENG Kui, SONG Jie, ZHANG Ye. Effects of ultrasound-guided adductor canal block combined with general anesthesia on postoperative pain and cognitive function in elderly patients undergoing total knee arthroplasty [J]. Tianjin Medical Journal, 2024, 52(5): 523-527. |
[8] | JIA Xirui, LIU Lijie. The role and research progress of microglia in sepsis related encephalopathy [J]. Tianjin Medical Journal, 2024, 52(5): 557-560. |
[9] | HE Yanan, CAI Xiang, QIU Baiyi, SUN Bangmei, LI Linghua. Study on the therapeutic effect of andrographolide on psoriasis mouse model by regulating cGAS-STING signal pathway [J]. Tianjin Medical Journal, 2024, 52(4): 379-386. |
[10] | XIAO Yuqian, SUN Kexin, WAN Jun, CHEN Shuying, CHEN Limin, WANG Yan, BAI Yanjie. Research progress of RNA m6A methylation in post-stroke cognitive impairment [J]. Tianjin Medical Journal, 2024, 52(3): 331-336. |
[11] | WANG Xinyao, YANG Hui, LI Bingbing. Research progress of mesenchymal stem cells in endometriosis [J]. Tianjin Medical Journal, 2024, 52(2): 215-219. |
[12] | TU Changming, TIAN Yuan, WANG Pengcheng, REN Peng, ZHAO Yinsheng. Relationship between SII, RAR and severity of disease and respiratory failure in patients with AECOPD [J]. Tianjin Medical Journal, 2024, 52(12): 1317-1321. |
[13] | CAI Dengta, CHANG Jingyi, JIA Shanshan, TU Yinqiong. Roxadustat improves myocardial ischemia-reperfusion injury in mice by inhibiting apoptosis and inflammatory response [J]. Tianjin Medical Journal, 2024, 52(11): 1146-1151. |
[14] | XU Fang, LIANG Yi, HE Yong, XU Julong. Impact of sufentanil on liver injury in burn-induced sepsis rats by regulating JAK2/STAT3 signaling pathway [J]. Tianjin Medical Journal, 2024, 52(11): 1158-1163. |
[15] | LIU Haoying, SHI Tianwei. Progress of the aryl hydrocarbon receptor in inflammatory skin diseases [J]. Tianjin Medical Journal, 2024, 52(11): 1221-1225. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||